Does Hypoxia and Stress Erythropoiesis Compromise Cardiac Function in Healthy Adults A Randomized Trial
Metadatos
Afficher la notice complèteAuteur
Arrebola Moreno, Antonio Luis; Casuso Pérez, Rafael Antonio; Aragón Vela, Jerónimo; Rodríguez Huertas, Jesús FranciscoEditorial
Springer
Materia
Altitude Haematology Heart Doping
Date
2022-11-05Referencia bibliográfica
Arrebola-Moreno, A.L... [et al.]. Does Hypoxia and Stress Erythropoiesis Compromise Cardiac Function in Healthy Adults? A Randomized Trial. Sports Med - Open 8, 137 (2022). [https://doi.org/10.1186/s40798-022-00531-x]
Patrocinador
World Anti-Doping Agency ISF17R02NNRésumé
Objectives: To investigate whether recombinant human erythropoietin (rHuEPO) injections during an altitude training
camp impact heart function.
Methods: Thirty (12 women) moderately trained subjects stayed at 2320 m altitude for 4 weeks while training.
Subjects were randomized to placebo (isotonic saline) or rHuEPO (20 IU/kg body weight) i.v. injections. Transthoracic
echocardiography imaging was acquired 3 days after arrival to altitude and prior to the first placebo or rHuEPO injection
as well as one day after the last rHuEPO injection three weeks later.
Results: rHuEPO did not alter cardiovascular morphology parameters, systolic or diastolic function. In the placebo
group, altitude exposure improved left ventricle (LV) systolic function due to an increased twist angle but rHuEPO had
no additional effects. Pulmonary arterial systolic pressure was unaffected in either group. Notably, rHuEPO hampered
LV untwist rate without affecting LV early filling.
Conclusion: rHuEPO provided during mild altitude exposure does not cause any major effects on heart function. The
observed alteration in LV untwist induced by rHuEPO is unlikely to have a meaningful clinical effect.